The choice of a gonadotropin-releasing hormone analog influences outcome of in vitro fertilization treatment.
OBJECTIVE
Our purpose was to determine if there is a difference in outcome associated with choice of gonadotropin-releasing hormone analog in in vitro fertilization treatment cycles.


METHODS
A retrospective analysis of 510 consecutive in vitro fertilization cycles with patient-selected use of either nafarelin (Synarel) or leuprolide (Lupron) was performed.


RESULTS
Of 510 consecutive patient cycles, 284 patients (56%) chose nafarelin and 226 (44%) chose leuprolide. In the nafarelin group 64 cycles (34% of retrievals) resulted in deliveries. In the leuprolide group 37 (24%) resulted in delivery (p < 0.05). There were 260 patients in their first cycle of treatment, with 157 (60%) choosing nafarelin, resulting in 33 deliveries (34% per retrieval). Leuprolide, used in 103 (40%) of first cycles, resulted in 12 deliveries (20% per retrieval), (p = 0.052).


CONCLUSIONS
In a large population of unselected patients undergoing in vitro fertilization the choice of nafarelin was associated with a significantly better outcome in terms of successful pregnancies achieved.
Martin
M C
MC
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco 94143-0132.
Givens
C R
CR
Schriock
E D
ED
Glass
R H
RH
Dandekar
P V
PV
D000328:Adult; D005260:Female; D005307:Fertilization in Vitro / Q000187:drug effects*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D017274:Nafarelin / Q000627:therapeutic use*; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D012189:Retrospective Studies
D017274:Nafarelin; D016729:Leuprolide